Cargando…
A surrogate marker for Aβ42 production in the CNS
Alzheimer's disease (AD) is the most common cause of dementia. There are currently no effective treatments that may delay the onset, slow the progression or prevent the disease. Unless such treatments are developed, the number of AD cases is expected to double in the next 30 years. There is ove...
Autor principal: | Holtzman, David M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
WILEY-VCH Verlag
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3378130/ https://www.ncbi.nlm.nih.gov/pubmed/20049720 http://dx.doi.org/10.1002/emmm.200900030 |
Ejemplares similares
-
Gaining the hard yard: pre-clinical evaluation of lentiviral-mediated gene therapy for the treatment of β-thalassemia
por: Milsom, Michael D, et al.
Publicado: (2010) -
VEGF sticky-trap: the first report of a non-systemically acting angiogenesis inhibitor
por: Favara, David M, et al.
Publicado: (2014) -
Converting cancer mutations into therapeutic opportunities
por: O'Brien, Tom, et al.
Publicado: (2009) -
In a flurry of PINK, mitochondrial bioenergetics takes a leading role in Parkinson's disease
por: Murphy, Anne N
Publicado: (2009) -
IGF2: The Achilles' heel of p53-deficiency?
por: Clermont, Frederic, et al.
Publicado: (2012)